We are pleased to partner with the Muscular Dystrophy Association (MDA) to bring you coverage from the MDA Clinical & Scientific Conference.
Also covering MDA Conference 2026:
Discussion
Cartesian Therapeutics’ experimental cell therapy Descartes-08 outperformed a placebo at easing symptoms of generalized myasthenia gravis (gMG) in patients who test positive for self-reactive antibodies targeting the acetylcholine receptor (AChR) protein. That’s according…
Discussion
Rystiggo (rozanolixizumab-noli) provides consistent symptom relief for people with generalized myasthenia gravis (gMG) across more than a dozen treatment cycles, according to a new analysis of clinical trial data. The approved UCB…
Discussion
At this year’s Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, researchers and clinicians are talking about the central role of patients, families, and caregivers in driving change for people living with neuromuscular diseases.
Discussion
Johnson & Johnson (J&J) has launched a Phase 3b clinical trial to compare the efficacy of two approved treatments for generalized myasthenia gravis (gMG). The trial, dubbed EPIC (NCT07217587), is specifically testing…
Get regular updates to your inbox.
